136 related articles for article (PubMed ID: 9422107)
1. Anti-EBNA-1 (carboxy-half) IgG antibodies as a seroepidemiological marker for Epstein-Barr virus infection.
Nebel-Schickel H; Hinderer W; Saavedra C; Schmutzler R; Horn J; Vornhagen R; Sonneborn HH
Beitr Infusionsther Transfusionsmed; 1994; 32():134-7. PubMed ID: 9422107
[TBL] [Abstract][Full Text] [Related]
2. A systematic study of Epstein-Barr virus serologic assays following acute infection.
Rea TD; Ashley RL; Russo JE; Buchwald DS
Am J Clin Pathol; 2002 Jan; 117(1):156-61. PubMed ID: 11789721
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of IgG-IgM antibodies against the Epstein-Barr virus nuclear antigen (EBNA-1) using ELISA].
Martínez Zapico R; Sobejano L; Llamazares I; Ladrón de Guevara C
Enferm Infecc Microbiol Clin; 1992 May; 10(5):281-3. PubMed ID: 1327168
[TBL] [Abstract][Full Text] [Related]
4. Seroepidemiological study of Epstein-Barr virus infection in Bangladesh.
Haque T; Iliadou P; Hossain A; Crawford DH
J Med Virol; 1996 Jan; 48(1):17-21. PubMed ID: 8825705
[TBL] [Abstract][Full Text] [Related]
5. [A comparison of the detection of IgM antibodies against the viral capsid antigen (VCA) of EBV (Epstein-Barr virus) in various groups of patients, using indirect immunofluorescence, indirect ELISA and reverse ELISA. Study of the diagnostic efficacy of the anti-VCA EBV IgM ELISA-VIDITEST kit].
Pumannová M; Rezbová M; Svecová M; Hrbácková H; Novotná M; Ochotná J; Roubalová K
Klin Mikrobiol Infekc Lek; 2004 Aug; 10(4):186-90. PubMed ID: 15328576
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus antibodies in patients with laryngeal and hypopharyngeal cancer.
Morshed K; Polz-Dacewicz M; Szymański M; Rajtar B; Ziaja-Sołtys M; Gołabek W
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):227-31. PubMed ID: 15323196
[TBL] [Abstract][Full Text] [Related]
7. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
[TBL] [Abstract][Full Text] [Related]
9. The serological signs of the Epstein-Barr virus (EBV) activity in the elderly.
Ternák G; Szúcs G; Uj M
Acta Microbiol Immunol Hung; 1997; 44(2):133-40. PubMed ID: 9330661
[TBL] [Abstract][Full Text] [Related]
10. Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.
Yamazaki M; Kitamura R; Kusano S; Eda H; Sato S; Okawa-Takatsuji M; Aotsuka S; Yanagi K
Clin Exp Immunol; 2005 Mar; 139(3):558-68. PubMed ID: 15730403
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of three different assays for the assessment of Epstein Barr Virus immunological status.
Altuglu I; Bozkurt H; Samlioglu P; Zeytinoglu A
New Microbiol; 2007 Oct; 30(4):393-8. PubMed ID: 18080674
[TBL] [Abstract][Full Text] [Related]
12. Serological diagnosis of Epstein-Barr virus infection by novel ELISAs based on recombinant capsid antigens p23 and p18.
Färber I; Hinderer W; Rothe M; Lang D; Sonneborn HH; Wutzler P
J Med Virol; 2001 Apr; 63(4):271-6. PubMed ID: 11241457
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a multiplex fluorescent microsphere immunoassay for the determination of epstein-barr virus serologic status.
Martins TB; Litwin CM; Hill HR
Am J Clin Pathol; 2008 Jan; 129(1):34-41. PubMed ID: 18089487
[TBL] [Abstract][Full Text] [Related]
14. [Performance of the VIDAS automated immunoassay for the determination of Epstein-Barr virus serological status].
De Ory F; Guisasola ME; Sanz JC; García-Bermejo I
Enferm Infecc Microbiol Clin; 2012 Dec; 30(10):618-20. PubMed ID: 22854635
[TBL] [Abstract][Full Text] [Related]
15. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis.
Blaschke S; Schwarz G; Moneke D; Binder L; Müller G; Reuss-Borst M
J Rheumatol; 2000 Apr; 27(4):866-73. PubMed ID: 10782808
[TBL] [Abstract][Full Text] [Related]
17. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D.
Chow KC; Ma J; Lin LS; Chi KH; Yen SH; Liu SM; Liu WT; Chen WK; Chang TH; Chen KY
Cancer Epidemiol Biomarkers Prev; 1997 May; 6(5):363-8. PubMed ID: 9149897
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
19. [Epstein-Barr virus antibodies: review of results from repeated examinations in 208 hemodialyzed patients].
Korcáková L
Vnitr Lek; 1995 Jun; 41(6):377-9. PubMed ID: 7676656
[TBL] [Abstract][Full Text] [Related]
20. Serological diagnosis of nasopharyngeal carcinoma by enzyme linked immunosorbent assay: optimization, standardization and diagnostic criteria.
Ng MH; Chen HL; Luo RX; Chan KH; Woo PC; Sham JS; Huang J; Seto WH; Smith P; Griffin BE
Chin Med J (Engl); 1998 Jun; 111(6):531-6. PubMed ID: 11245074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
